Exemplary cases of individualization of biological therapy
The use of biological drugs consisting of large molecules has in recent years expanded to new indications and new specialties. These drugs are most commonly proteins possessing the structure of an antibody or a receptor, and treatment with them is significantly more expensive than that carried out with conventional small molecule drugs. Determination of drug levels and emerging antibodies form the basis of individualization. They will enable better treatment results with simultaneous avoidance of unnecessary medications, excessive doses--and extra costs. We demonstrate the individualization of TNF-α blocker therapy through patient cases in various situations.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
Duodecim; laaketieteellinen aikakauskirja - 132(2016), 4 vom: 20., Seite 387-90 |
| Sprache: |
Finnisch |
|---|
| Weiterer Titel: |
Esimerkkitapauksia biologisen hoidon yksilöllistämisestä |
|---|
| Beteiligte Personen: |
Sipponen, Taina [VerfasserIn] |
|---|
| Themen: |
Biological Products |
|---|
| Anmerkungen: |
Date Completed 03.05.2016 Date Revised 28.03.2016 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM258815663 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM258815663 | ||
| 003 | DE-627 | ||
| 005 | 20231224185831.0 | ||
| 007 | tu | ||
| 008 | 231224s2016 xx ||||| 00| ||fin c | ||
| 028 | 5 | 2 | |a pubmed24n0862.xml |
| 035 | |a (DE-627)NLM258815663 | ||
| 035 | |a (NLM)27017791 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fin | ||
| 100 | 1 | |a Sipponen, Taina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exemplary cases of individualization of biological therapy |
| 246 | 3 | 3 | |a Esimerkkitapauksia biologisen hoidon yksilöllistämisestä |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2016 | ||
| 500 | |a Date Revised 28.03.2016 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The use of biological drugs consisting of large molecules has in recent years expanded to new indications and new specialties. These drugs are most commonly proteins possessing the structure of an antibody or a receptor, and treatment with them is significantly more expensive than that carried out with conventional small molecule drugs. Determination of drug levels and emerging antibodies form the basis of individualization. They will enable better treatment results with simultaneous avoidance of unnecessary medications, excessive doses--and extra costs. We demonstrate the individualization of TNF-α blocker therapy through patient cases in various situations | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Biological Products |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 700 | 1 | |a Isomäki, Pia |e verfasserin |4 aut | |
| 700 | 1 | |a Leinonen, Sanna |e verfasserin |4 aut | |
| 700 | 1 | |a Mälkönen, Tarja |e verfasserin |4 aut | |
| 700 | 1 | |a Jokiranta, Sakari |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Duodecim; laaketieteellinen aikakauskirja |d 1945 |g 132(2016), 4 vom: 20., Seite 387-90 |w (DE-627)NLM000016136 |x 0012-7183 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2016 |g number:4 |g day:20 |g pages:387-90 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2016 |e 4 |b 20 |h 387-90 | ||